About Senti Biosciences

Senti Biosciences develops proprietary Gene Circuits using synthetic biology to reprogram cells for targeted cancer therapies, enabling precise elimination of cancer cells while sparing healthy tissue. Their lead product candidate, SENTI-202, is designed for the treatment of acute myeloid leukemia, addressing the need for more effective and specific cancer treatments.

```xml <problem> Current cancer treatments often lack the specificity needed to target cancer cells effectively, leading to damage of healthy tissue and severe side effects for patients. This lack of precision limits the effectiveness of therapies and reduces the overall quality of life for individuals undergoing treatment. </problem> <solution> Senti Biosciences is developing a new generation of cell therapies using synthetic biology and proprietary Gene Circuits to reprogram cells. These Gene Circuits, constructed from novel DNA sequences, enable the therapeutics to sense inputs, compute decisions, and respond dynamically within the cellular environment. By programming cells with biological logic, Senti Bio's approach aims to create cancer therapeutics that precisely target and eliminate cancer cells while sparing healthy tissue and controlling drug expression. Their lead product candidate, SENTI-202, is currently in clinical trials for the treatment of acute myeloid leukemia (AML). </solution> <features> - Gene Circuit technology platform for programming cells with synthetic biology - Off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells for enhanced targeting - SENTI-202 product candidate targeting CD33 and/or FLT3 for AML and other blood cancers - SENTI-301A/SN301A product candidate targeting GPC3 for hepatocellular carcinoma (HCC) and other solid tumors (partnered with Celest Therapeutics) - Multiple gene therapy programs for eye, CNS, and liver diseases (partnered with Spark Therapeutics) - Multiple iPSC cell therapy programs for regenerative medicine (partnered with BlueRock Therapeutics) </features> <target_audience> The primary target audience includes patients with various forms of cancer, such as acute myeloid leukemia, hepatocellular carcinoma, and other solid tumors and blood cancers, as well as those with eye, CNS, and liver diseases. </target_audience> ```

What does Senti Biosciences do?

Where is Senti Biosciences located?

Senti Biosciences is based in South San Francisco, United States.

When was Senti Biosciences founded?

Senti Biosciences was founded in 2016.

How much funding has Senti Biosciences raised?

Senti Biosciences has raised 47600000.

Location

South San Francisco, United States

Founded

2016

Funding

47600000

Employees

59 employees

Major Investors

Celadon Partners

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Senti Biosciences

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

sentibio.com 10K+

Crunchbase

Founded 2016 – South San Francisco, United States

Funding

Estimated Funding

$20M+

Major Investors

Celadon Partners

Team (50+)

No team information available.

Company Description

Problem

Current cancer treatments often lack the specificity needed to target cancer cells effectively, leading to damage of healthy tissue and severe side effects for patients. This lack of precision limits the effectiveness of therapies and reduces the overall quality of life for individuals undergoing treatment.

Solution

Senti Biosciences is developing a new generation of cell therapies using synthetic biology and proprietary Gene Circuits to reprogram cells. These Gene Circuits, constructed from novel DNA sequences, enable the therapeutics to sense inputs, compute decisions, and respond dynamically within the cellular environment. By programming cells with biological logic, Senti Bio's approach aims to create cancer therapeutics that precisely target and eliminate cancer cells while sparing healthy tissue and controlling drug expression. Their lead product candidate, SENTI-202, is currently in clinical trials for the treatment of acute myeloid leukemia (AML).

Features

Gene Circuit technology platform for programming cells with synthetic biology

Off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells for enhanced targeting

SENTI-202 product candidate targeting CD33 and/or FLT3 for AML and other blood cancers

SENTI-301A/SN301A product candidate targeting GPC3 for hepatocellular carcinoma (HCC) and other solid tumors (partnered with Celest Therapeutics)

Multiple gene therapy programs for eye, CNS, and liver diseases (partnered with Spark Therapeutics)

Multiple iPSC cell therapy programs for regenerative medicine (partnered with BlueRock Therapeutics)

Target Audience

The primary target audience includes patients with various forms of cancer, such as acute myeloid leukemia, hepatocellular carcinoma, and other solid tumors and blood cancers, as well as those with eye, CNS, and liver diseases.